Business Context and Reporting Period
This Form 8-K reports on events occurring on June 4, 2021, specifically the 2021 Annual Meeting of Stockholders for Zentalis Pharmaceuticals, Inc. (ZNTL). The filing details the election of directors, ratification of auditors, and approval of an amended employee stock purchase plan.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the approval of the amendment and restatement of the 2020 Employee Stock Purchase Plan. Key modifications include:
- Share Reserve Increase: The maximum number of shares authorized for issuance is set at 2,000,000 shares.
- Elimination of Evergreen Provision: The plan removes the previous provision that allowed for an annual increase in available shares on January 1 of each year.
Outlook, Risks, and Management Commentary
Management commentary is limited to the procedural outcomes of the Annual Meeting. No specific guidance, forward-looking financial outlook, or new risk factors were disclosed in this document. The filing confirms that the Restated Plan became effective on March 15, 2021, subject to the stockholder approval received on June 4, 2021.
Investor Verification Checklist
- Verify the full text of the Restated Plan filed as Exhibit 99.1 to the Form S-8 registration statement (filed March 19, 2021) for complete terms.
- Confirm the election results for Class I Directors: Kimberly Blackwell, M.D. and Enoch Kariuki, Pharm.D. were elected.
- Note that Ernst & Young LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2021.
- Review the definitive proxy statement filed on April 23, 2021, for detailed descriptions of the proposals voted upon.